SLC5A2 and stroke disorder: SGLT2 inhibitors were also superior to DPP-4 inhibitors in terms of hospitalisation for HF, with a 33% reduction in rate, but also in terms of myocardial infarction and stroke, with a 14% reduction in rates [93].